Deadliest Cancer Stunned By New Pill

A new drug just did something doctors have been waiting decades to see in pancreatic cancer — it nearly doubled how long patients lived after their first treatment failed.

Quick Take

Daraxonrasib extended median survival to 13.2 months versus 6.7 months for chemotherapy in a major phase 3 trial.
The drug targets RAS gene mutations, which drive the vast majority of pancreatic cancers.
The trial result was statistically powerful, with a hazard ratio of 0.40 — meaning patients on daraxonrasib had 60% lower risk of death at any given point.
Full regulatory review is still ahead, but experts are calling this the most meaningful advance in second-line pancreatic cancer treatment in years.

Why Pancreatic Cancer Has Been So Hard to Beat

Pancreatic cancer kills fast. Most patients are diagnosed late, when the cancer has already spread. For decades, chemotherapy was the only real option — and it was never very good. In the second-line setting, meaning after the first treatment stops working, median survival hovered around six to seven months. Doctors had little else to offer. That grim reality is what makes the new daraxonrasib data so striking.

The cancer is also notoriously hard to target with precision drugs. About 90% of pancreatic cancers carry a mutation in the RAS gene family. For a long time, scientists called RAS “undruggable.” The proteins produced by mutated RAS genes are slippery — they don’t have a good pocket for a drug molecule to grab onto. Decades of attempts failed. That made the RAS mutation a frustrating dead end, even as it remained the most obvious target in the disease.

What Daraxonrasib Does Differently

Daraxonrasib is what researchers call a RAS(ON) multi-selective inhibitor. Instead of targeting just one type of RAS mutation, it hits multiple active forms of the mutated protein. That broader reach matters because pancreatic cancer patients can carry different RAS variants. The drug is taken orally, which is a practical advantage over intravenous chemotherapy. Revolution Medicines developed the drug and ran the global phase 3 RASolute 302 trial that produced the headline results reported in April 2026.

The trial compared daraxonrasib directly against standard chemotherapy in patients with previously treated metastatic pancreatic cancer. The results were not close. Median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy. The hazard ratio was 0.40, and the p-value was less than 0.0001 — meaning the chance this result was random is essentially zero. The drug also improved progression-free survival, the measure of how long patients go before their cancer gets worse again. ^[1]

How Significant Is a Hazard Ratio of 0.40

Most people hear “13 months versus 7 months” and think in terms of raw numbers. But oncologists focus on the hazard ratio. A hazard ratio of 0.40 means that at any point during the trial, patients on daraxonrasib had 60% lower risk of dying compared to those on chemotherapy. ^[1] That is an unusually large effect size for a solid tumor trial. For context, many cancer drugs that win approval show hazard ratios in the 0.70 to 0.80 range. A result of 0.40 in a randomized phase 3 trial is the kind of number that gets a standing ovation at a medical conference — and it did, at ASCO 2026 in Chicago. ^[2]

Earlier phase 1 and 2 studies had already shown daraxonrasib was active against RAS-mutated solid tumors. ^[6] The phase 3 trial confirmed and dramatically extended that signal. The Pancreatic Cancer Action Network noted it as the first RAS inhibitor to show this kind of survival benefit in this patient population. ^[5] That label — first — carries real weight in a disease where so many drugs have failed.

What Still Needs to Happen Before Patients Can Get It

The data released in April 2026 are topline results from the company itself. Full peer-reviewed publication and regulatory review by the Food and Drug Administration are still ahead. That is a normal part of the process, not a red flag. But it does mean the complete picture — including detailed safety data, subgroup breakdowns, and long-term follow-up — has not yet been fully aired in public. Oncologists are appropriately enthusiastic but also waiting for that fuller look before calling this a permanent standard of care. ^[3]

The pattern here is familiar in cancer medicine. A company announces strong trial results, the medical press covers the headline number, and the deeper analysis comes later through publication and regulatory filings. That slower process exists for good reason. Patients and families hearing about this drug deserve both the honest hope the data provides and a clear understanding that it is not yet approved or widely available. The evidence so far is genuinely compelling. The next step is letting the full scientific process finish what this trial started. ^[4]